Tubos de ensaio

In vivo Drug Screening Platform

Efficacy Predict Toll for Cancer Research


Companion animals can be used as a informative model in the preclinical development and discovery of novel cancer treatment.
Studies in dogs provide guidance for conducting similar investigation in human patients.

This model helps to evaluate the efficacy  and feasibility of new compounds and can inform the GO/NO-GO decision in clinical drug development

Selected compound with anti-cancer activity demonstrated in vitro and mice studies 

We design and conduct 

companion animals trials in

our veterinary international

practices network

High predictivity

efficacy results

Go/No-Go Decision

Examples of Preclinical Investigation in Companion Animals 


FDA approved for human use

Companion animals trial suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).


Phase II human trial completed

Demonstration of target inhibition in companion animal trial. Studies in dogs were used as a proof of target and refined measure of drug exposure


FDA approved for human use

Validation of biomarker test for use in human trials; dose modulation. Companion animals trial demonstrated efficacy and surrogate endpoint.


Phase III human trials

Proof-of-target for IND application; defined PK/PD relationship. Determined toxicity, biomarkers, and biologic activity


Phase I human trials ongoing

PK, PD, efficacy and toxicity studies were conducted in companion animals naturally affected with malignant melanoma

Decision was made to not move forward with human studies based on companion animals trials results.


Assessed single-agent activity and toxicity for development of tolerable dosing regimen.

Determined dosing regimen and supportive care protocolsin companion animals. Identified adverse events, dose, and regimen.

Phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics, supporting their further clinical development.

Companion animal trials confirmed inhibition target and tumor response. Masitinib is EMA-approved for veterinary use.